Internal medicine, Ovarian cancer, Cancer research, Pathology and Cancer are her primary areas of study. Her Internal medicine research integrates issues from Gastroenterology, Endocrinology and Oncology. Her research integrates issues of Stage and Epidermal growth factor in her study of Oncology.
Her Ovarian cancer research is multidisciplinary, incorporating perspectives in Laparotomy, Class III β-tubulin and Laparoscopy. Her work deals with themes such as Radiology and Histopathology, which intersect with Cancer. Gabriella Ferrandina has researched Surgery in several fields, including Cervical cancer and Radical surgery.
Her scientific interests lie mostly in Internal medicine, Surgery, Ovarian cancer, Oncology and Cervical cancer. Her Internal medicine research incorporates elements of Gastroenterology and Endocrinology. Her Ovarian cancer research is multidisciplinary, relying on both Cancer research, Carboplatin, Paclitaxel, Ovary and Carcinoma.
Her studies deal with areas such as Gemcitabine, Disease and Trabectedin as well as Oncology. Her Cervical cancer study also includes fields such as
Her primary scientific interests are in Internal medicine, Surgery, Cervical cancer, Oncology and Stage. Her work is connected to Ovarian cancer, Chemotherapy, Disease, Progression-free survival and Phases of clinical research, as a part of Internal medicine. Her Surgery study combines topics from a wide range of disciplines, such as Lymphadenectomy and Radical Hysterectomy.
Her Cervical cancer research includes elements of Lymph node, Radiology, Locally advanced, Chemoradiotherapy and Radical surgery. Her biological study deals with issues like Trabectedin, which deal with fields such as Platinum sensitive and Pegylated Liposomal Doxorubicin. As a part of the same scientific family, Gabriella Ferrandina mostly works in the field of Stage, focusing on Radiation therapy and, on occasion, Clinical trial.
Her scientific interests lie mostly in Surgery, Internal medicine, Ovarian cancer, Oncology and Cervical cancer. In her research, Clear cell carcinoma, Abdominal mass, Rectus abdominis muscle, Abdominal wall and Carcinoma is intimately related to Radical Hysterectomy, which falls under the overarching field of Surgery. Her Ovarian cancer research incorporates elements of Survival rate, Invadopodia, Proportional hazards model, Cortactin and RhoC.
Her Oncology research incorporates themes from Disease and Chemotherapy. Her Cervical cancer research also works with subjects such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
A. Bellacosa;D. De Feo;A. K. Godwin;D. W. Bell.
International Journal of Cancer (1995)
CLASS III BETA-TUBULIN OVEREXPRESSION IS A PROMINENT MECHANISM OF PACLITAXEL RESISTANCE IN OVARIAN CANCER PATIENTS
Simona Mozzetti;Cristiano Ferlini;Paola Concolino;Flavia Filippetti.
Clinical Cancer Research (2005)
Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target.
G. Scambia;F. O. Ranelletti;P. Benedetti Panici;R. De Vincenzo.
Cancer Chemotherapy and Pharmacology (1994)
Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma
M Maurizi;G Almadori;G Ferrandina;M Distefano.
British Journal of Cancer (1996)
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Sandro Pignata;Giovanni Scambia;Dionyssios Katsaros;Ciro Gallo.
Lancet Oncology (2014)
Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer
Gabriella Ferrandina;Manuela Ludovisi;Domenica Lorusso;Sandro Pignata.
Journal of Clinical Oncology (2008)
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study.
Anna Fagotti;Gabriella Ferrandina;Francesco Fanfani;Alfredo Ercoli.
Annals of Surgical Oncology (2006)
Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients
Gabriella Ferrandina;Gian Franco Zannoni;Enrica Martinelli;Amelia Paglia.
Clinical Cancer Research (2006)
Expression of CD133-1 and CD133-2 in ovarian cancer.
G. Ferrandina;G. Bonanno;L. Pierelli;A. Perillo.
International Journal of Gynecological Cancer (2008)
Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma.
Anna Fagotti;Gabriella Ferrandina;Francesco Fanfani;Giorgia Garganese.
American Journal of Obstetrics and Gynecology (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: